This study was carried out to assess the protective bone-sparing effect of carnitine with anti-inflammatory properties on chronic inflammation-induced bone loss in ovariectomised (OVX) rats. A total of 64 rats were divided into eight groups. Sixteen rats were sham-operated (SH) while the others were ovariectomised (OVX). (1) SH, (2) sham + inflammation (SHinf), (3) OVX, (4) ovariectomy + inflammation (OVXinf), (5) OVX + CAR1, (6) OVX + CAR2, (7) OVXinf + CAR1, (8) OVXinf + CAR2. After the ovariectomy surgery, all the groups (3, 4, 5, 6, 7, and 8) were allowed to recover for two months. Sixty days after the OVX, inflammation was induced by subcutaneous injections of talc in groups 2, 4, 7, and 8. Group 5 and 7 were given 50 mg/kg CAR; Group 6 and 8 were given 100 mg/kg CAR from the 60th to the 80th day. Serum levels of TNF-α, IL-1, IL-6, OP, and OC were assessed to determine inflammation and to evaluate osteoblastic activity. Bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry in femur bones of rats. Carnitine administration was able to restore BMD up to values measured in both the OVX and the SH animals. The serum levels of TNF-α, IL-1β, and IL-6 were increased significantly in the OVXinf rats compared with the SH group. In OVX rats, inflammation which is evaluated by serum cytokine levels exacerbated this bone loss, as supported by values of BMD of the total femur. The two different doses of carnitine reduced bone loss and improved inflammatory biomarkers.
CooperC. Epidemiology of osteoporosis. Osteoporos Int1999; 9(Suppl 2): S2–8.
2.
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. The Am J Med 1993;94(6):646–50.
3.
CummingsSRMeltonLJ. Epidemiology and outcomes of osteoporotic fractures. Lancet2002; 359(9319): 1761–7.
4.
AkessonK. New approaches to pharmacological treatment of osteoporosis. Bull World Health Org2003; 81(9): 657–64.
5.
LelovasPPXanthosTTThomaSELyritisGPDontasIA. The laboratory rat as an animal model for osteoporosis research. Comparative Medicine2008; 58(5): 424–30.
6.
ManolagasSC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev2000; 21(2): 115–37.
7.
ArmourKERalstonSH. Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. Endocrinology1998; 139(2): 799–802.
8.
RiggsBLKhoslaSMeltonLJ3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Min Res1998; 13(5): 763–73.
9.
CompstonJE. Sex steroids and bone. Physiolog Rev2001; 81(1): 419–47.
10.
FaloniAPSasso-CerriEKatchburianECerriPS. Decrease in the number and apoptosis of alveolar bone osteoclasts in estrogen-treated rats. J Periodontal Res2007; 42(3): 193–201.
11.
PfeilschifterJKoditzRPfohlMSchatzH. Changes in proinflammatory cytokine activity after menopause. Endocr Rev2002; 23(1): 90–119.
12.
CarlstenHNilssonNJonssonRBackmanKHolmdahlRTarkowskiA. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL lpr/lpr mice. Cell Immunol1992; 144(1): 190–202.
13.
JosefssonETarkowskiACarlstenH. Anti-inflammatory properties of estrogen. I. In vivo suppression of leukocyte production in bone marrow and redistribution of peripheral blood neutrophils. Cell Immunol1992; 142(1): 67–78.
14.
da SilvaJAColville-NashPSpectorTDScottDLWilloughbyDA. Inflammation-induced cartilage degradation in female rodents. Protective role of sex hormones. Arthritis Rheum1993; 36(7): 1007–13.
15.
JanssonLHolmdahlR. Estrogen-mediated immunosuppression in autoimmune diseases. Inflamm Res1998; 47(7): 290–301.
16.
RossouwJEAndersonGLPrenticeRLLaCroixAZKooperbergCStefanickMLJacksonRDBeresfordSAHowardBVJohnsonKCKotchenJMOckeneJ. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002; 288(3): 321–33.
17.
Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet1997; 350(9084): 1047–59.
18.
MeadeTWVickersMR. HRT and cardiovascular disease. J Epidemiol Biostat1999; 4(3): 165–90.
19.
HaliciZBorekciBOzdemirYCadirciESuleymanH. Protective effects of amlodipine and lacidipine on ovariectomy-induced bone loss in rats. Eur J Pharmacol2008; 579(1–3): 241–5.
20.
HayatullinaZMuhammadNMohamedNSoelaimanIN. Virgin coconut oil supplementation prevents bone loss in osteoporosis rat model. Evidence-based complementary and alternative medicine. eCAM2012; 2012: 237236–237236.
21.
JumaSSEzzat-ZadehZKhalilDAHooshmandSAkhterMArjmandiBH. Soy protein with or without isoflavones failed to preserve bone density in gonadal hormone-deficient male rat model of osteoporosis. Nutr Res2012; 32(9): 694–700.
22.
MuhammadNLukeDAShuidANMohamedNSoelaimanIN. Two different isomers of vitamin e prevent bone loss in postmenopausal osteoporosis rat model. Evidence-based complementary and alternative medicine. eCAM2012; 2012: 161527–161527.
23.
StepanJJPospichalJPreslJPacovskyV. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone1987; 8(5): 279–84.
24.
KrempienBVukicevicSVogelMStavljenicABucheleR. Cellular basis of inflammation-induced osteopenia in growing rats. J Bone Min Res1988; 3(5): 573–82.
25.
BrassEPHiattWR. The role of carnitine and carnitine supplementation during exercise in man and in individuals with special needs. J Am Coll Nutr1998; 17(3): 207–15.
26.
Nelson DL, Cox MM. Fatty acid catabolism. Lehninger principles of biochemistry. 4th ed, New York: W. H. Freeman & Company; 2004.
27.
ChiuKMKellerETCrenshawTDGravensteinS. Carnitine and dehydroepiandrosterone sulfate induce protein synthesis in porcine primary osteoblast-like cells. Calcif Tissue Int1999; 64(6): 527–33.
28.
ColucciSMoriGVairaSBrunettiGGrecoGManciniLSimoneGMSardelliFKoverechAZalloneAGranoM. L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int2005; 76(6): 458–65.
29.
XieHTangSYLiHLuoXHYuanLQWangDLiaoEY. L-carnitine protects against apoptosis of murine MC3T3-E1 osteoblastic cells. Amino Acid2008; 35(2): 419–23.
30.
CibulkaRRacekJPiknerRRajdlDTrefilLVeselaEStudenovskaMSirokaR. Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. Calcif Tissue Int2007; 81(2): 99–106.
31.
Izgut-UysalVNAgacADerinN. Effect of L-carnitine on carrageenan-induced inflammation in aged rats. Gerontology2003; 49(5): 287–92.
32.
BruunsgaardHPedersenMPedersenBK. Aging and proinflammatory cytokines. Curr Opin Hematol2001; 8(3): 131–6.
33.
ChoDCKimKTJeonYSungJK. A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat. Acta Neurochir2012; 154(12): 2215–23.
34.
LernerUH. Bone remodeling in post-menopausal osteoporosis. J Dental Res2006; 85(7): 584–95.
35.
HertrampfTSchleipenBVeldersMLaudenbachUFritzemeierKHDielP. Estrogen receptor subtype-specific effects on markers of bone homeostasis. Mol Cell Endocrinol2008; 291(1–2): 104–8.
36.
ChoJHChoDCYuSHJeonYHSungJKKimKT. Effect of dietary calcium on spinal bone fusion in an ovariectomized rat model. J Korean Neurosurg Soc2012; 52(4): 281–7.
37.
ReinholtFPHultenbyKOldbergAHeinegardD. Osteopontin–a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A1990; 87(12): 4473–5.
38.
HunterGKKyleCLGoldbergHA. Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J1994; 300(Pt 3): 723–8.
39.
HunterGKHauschkaPVPooleARRosenbergLCGoldbergHA. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J1996; 317(Pt 1): 59–64.
40.
SteitzSASpeerMYMcKeeMDLiawLAlmeidaMYangHGiachelliCM. Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification. Am J Pathol2002; 161(6): 2035–46.
41.
Kwak J, Zara JN, Chiang M, Ngo R, Shen J, James AW, Le K, Moon C, Zhang X, Gou Z, Ting K, Soo C. NELL-1 injection maintains long bone quantity and quality in an ovariectomy-induced osteoporotic senile rat model. Tissue Eng A 2013;19: 426–36.
42.
WadaCKataokaMSetoHHayashiNKidoJShinoharaYNagataT. High-turnover osteoporosis is induced by cyclosporin A in rats. J Bone Min Metabol2006; 24(3): 199–205.
43.
JilkaRLPasseriGGirasoleGCooperSAbramsJBroxmeyerHManolagasSC. Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6. Exper Hematol1995; 23(6): 500–6.
44.
PoliVBalenaRFattoriEMarkatosAYamamotoMTanakaHCilibertoGRodanGACostantiniF. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J1994; 13(5): 1189–96.
45.
PacificiR. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Min Res1996; 11(8): 1043–51.
46.
PfeilschifterJChenuCBirdAMundyGRRoodmanGD. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Min Res1989; 4(1): 113–8.
LiuYYanSJiCDaiWHuWZhangWMeiC. Metabolomic changes and protective effect of (L)-carnitine in rat kidney ischemia/reperfusion injury. Kidney Blood Pressure Res2012; 35(5): 373–81.
49.
LiJZhangHZhangC. Role of inflammation in the regulation of coronary blood flow in ischemia and reperfusion: mechanisms and therapeutic implications. J Mol Cell Cardiol2012; 52(4): 865–72.
50.
LavianoAMolfinoASeelaenderMFrascariaTBertiniGRamacciniCBolleaMRCitroGRossi FanelliF. Carnitine administration reduces cytokine levels, improves food intake, and ameliorates body composition in tumor-bearing rats. Cancer Invest2011; 29(10): 696–700.
51.
YuanYGuoHZhangYZhouDGanPLiangDMChenJY. Protective effects of L-carnitine on intestinal ischemia/reperfusion injury in a rat model. J Clin Med Res2011; 3(2): 78–84.
52.
LiuJHeadEKuratsuneHCotmanCWAmesBN. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann N Y Acad Sci2004; 1033: 117–31.
53.
FamularoGDe SimoneCTrinchieriVMoscaL. Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation. Ann N Y Acad Sci2004; 1033: 132–8.
54.
ThangasamyTJeyakumarPSittadjodySJoyeeAGChinnakannuP. L-carnitine mediates protection against DNA damage in lymphocytes of aged rats. Biogerontology2009; 10(2): 163–72.
55.
FamularoGDe SimoneC. A new era for carnitine?Immunol Today1995; 16(5): 211–3.
